Indefinite Delivery Contract 36E79724D0024
Award Date
6/17/24
Last Date to Order
6/16/25
Federal Agency
National Acquisition Center
Awardee
TG Therapeutics Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Department of Veterans Affairs National Acquisition Center has awarded a single-award Indefinite Delivery Contract (IDC) to Organon LLC for Infliximab Injection 100 mg/vial. The $119,538,562.32 contract has a base period of one year and four one-year option periods, running from September 1, 2023 through August 31, 2025. This IDC will provide an uninterrupted supply of the pharmaceutical product to the VA, Bureau of Prisons, and Indian Health Service through the VA's Pharmaceutical Prime...
The Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Indefinite Delivery Contract (IDC) to Teva Pharmaceuticals USA, Inc., a foreign-owned pharmaceutical manufacturer, for the supply of glatiramer acetate injections. The $64,352,514.80 contract has a base period of one year and four one-year option periods, running from August 2023 to August 2025. This IDC will ensure the delivery of approximately 208,000 syringes of glatiramer acetate 20mg/mL and 40mg/mL...
The U.S. Department of Veterans Affairs (VA) has awarded multiple Indefinite Delivery Vehicle (IDV) contracts to UCB, Inc., a global biopharmaceutical company, under the General Services Administration's Federal Supply Schedule for Pharmaceuticals and Drugs (FSS-61-IB).
The first IDV is a Blanket Purchase Agreement (BPA) with a $264,295.45 ceiling value that specifically covers the procurement of the drug ZilbrysQ to treat patients within the VA healthcare system. UCB, Inc. also holds a...
This Federal Supply Schedule contract was awarded by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 to TG Therapeutics Inc. The contract provides pharmaceuticals and drugs under GSA Schedule 65 IB, which covers drugs, pharmaceuticals, and hematology related products. With a potential value of $20 million and a period of performance through August 2026, this multiple-award contract aims to procure these medical supplies for VA...
This indefinite delivery contract (IDC) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Amgen USA Inc. for the provision of Calcitonin Gene-Related Peptide (CGRP) agents. The single-award contract has a ceiling value of $100,527,333.60 and a period of performance from February 26, 2025, to February 25, 2026, with four one-year option periods.
The contract aims to provide an uninterrupted source of supply for CGRP products to the VA, including its...
The U.S. Department of Veterans Affairs (VA) has awarded a $198 million Federal Supply Schedule (FSS) contract and a $50 million Blanket Purchase Agreement (BPA) to United Therapeutics Corporation, a self-certified small disadvantaged business and manufacturer of pharmaceutical goods. These Indefinite Delivery Vehicles (IDVs) allow the VA to efficiently procure United Therapeutics' specialized drug portfolio, including treatments for pulmonary arterial hypertension and certain types of...
The Department of Veterans Affairs awarded a multiple-award Federal Supply Schedule contract to Viela Bio, Inc. against the Pharmaceuticals and Drugs schedule for an estimated $12.98 million. This IDV establishes supply of pharmaceutical products to various VA medical centers nationwide through 2022.
A single-award Blanket Purchase Agreement against the same FSS schedule was also awarded to Viela Bio for an estimated $4.35 million. This BPA facilitates streamlined delivery of the...
This Indefinite Delivery Contract (IDC) was awarded by the National Acquisition Center, a civilian agency of the U.S. federal government, to Pfizer Inc. as the prime contractor. The contract has a total ceiling value of $83,732,812.80 and a period of performance from September 15, 2020 to September 14, 2025, including a base year and four one-year option periods.
The purpose of this IDC is to procure rituximab vials for the Department of Veterans Affairs, Department of Defense, Bureau of...
This federal contract IDV award is for a Federal Supply Schedule (FSS) contract under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, held by Pharmacyclics LLC, an AbbVie company. The contract has a ceiling value of $761,600,000 and a period of performance through August 28, 2025.
The contract vehicle is intended to provide the Department of Veterans Affairs and its Veterans Integrated Service Network 12 with a diverse selection of drugs, pharmaceuticals, and hematology-related products....
The Department of Veterans Affairs National Acquisition Center awarded Organon LLC a single-award Indefinite Delivery Contract valued at $22,611,464.85 to provide Trastuzumab (ONTRUZANT) 150mg. The contract has a base period plus four one-year option periods, with a total period of performance through November 14, 2025. This IDV will support the VA's Pharmaceutical Prime Vendor program, ensuring a consistent supply of the critical medication for veterans, military personnel, inmates, and...